INZY - Inozyme Pharma, Inc.

4
0.010   0.250%

Share volume: 1,459,443
Last Updated: 06-30-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$3.99
0.01
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 30%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
277.36%
2 Year
-9.50%
Key data
Stock price
$4.00
P/E Ratio 
0.00
DAY RANGE
$3.99 - $4.00
EPS 
-$1.68
52 WEEK RANGE
$1.05 - $4.00
52 WEEK CHANGE
$247.83
MARKET CAP 
58.459 M
YIELD 
N/A
SHARES OUTSTANDING 
64.562 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
2.11
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Axel Bolte
Region: US
Website: inozyme.com
Employees: 50
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Inozyme Pharma, Inc. engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

Recent news